ReviewFrontiers in cell and developmental biology2026
Lactylation in kidney diseases: a review of regulatory mechanisms and therapeutic prospects.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactylation, a novel post-translational modification (PTM) of proteins, plays a critical role in various diseases through the regulation of gene expression and metabolic reprogramming. Recent studies have increasingly highlighted its pathological and physiological relevance in kidney diseases. Lactylation exerts pleiotropic effects across diverse renal pathologies, from promoting fibrotic progression in Chronic kidney disease (CKD) to modulating immune evasion in clear cell renal cell carcinoma (ccRCC), thereby positioning it at the epicenter of metabolic-epigenetic interplay in kidney disease. This review systematically delineates the dynamic regulatory mechanisms of PTMs and their pivotal roles and current research status in kidney diseases, explores the latest advancements in lactylation research concerning CKD, acute kidney injury (AKI), and ccRCC, and discusses its potential as a therapeutic target. By synthesizing current findings, the article aims to offer new perspectives and directions for future treatments of kidney diseases and the development of targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.